Factors influencing the crystallization of monosodium urate: A systematic literature review Pathophysiology of musculoskeletal disorders

BMC Musculoskeletal Disorders

Volumn 16, Issue 1, 2015, Pages

  Chhana, Ashika ^a   Lee, Gerald ^a   Dalbeth, Nicola ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Crystal growth; Crystallization; Gout; Nucleation; Urate solubility

Indexed keywords

ALBUMIN; ALPHA GLOBULIN; BETA GLOBULIN; CHONDROITIN SULFATE; CONNECTIVE TISSUE GROWTH FACTOR; HUMAN SERUM ALBUMIN; HYALURONIC ACID; IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; SODIUM ION; URATE; URIC ACID; ANTIBODY; PROTEIN;

ARTHROPATHY; ARTICLE; DISSOLUTION; FEMALE; GOUT; HUMAN; HYPERURICEMIA; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; PH; RHEUMATOID ARTHRITIS; RISK FACTOR; SOLUBILITY; SYNOVIAL FLUID; SYSTEMATIC REVIEW; TEMPERATURE; X RAY DIFFRACTION; ANIMAL; CONNECTIVE TISSUE; CRYSTALLIZATION; METABOLISM;

ANIMALS; ANTIBODIES; CONNECTIVE TISSUE; CRYSTALLIZATION; GOUT; HUMANS; HYDROGEN-ION CONCENTRATION; PROTEINS; SOLUBILITY; URIC ACID;

EID: 84944029150     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/s12891-015-0762-4     Document Type: Article

References (57)

1. Faires J, McCarty D. Acute arthritis in man and dog after intrasynovial injection of sodium urate crystals. Lancet. 1962;280:682-5. doi: 10.1016/S0140-6736(62)90501-9.
2. Dalbeth N, Stamp L. Hyperuricaemia and gout: time for a new staging system? Ann Rheum Dis. 2014;73:1598-600. doi: 10.1136/annrheumdis-2014-205304.
3. Bardin T, Richette P. Definition of hyperuricemia and gouty conditions. Curr Opin Rheumatol. 2014;26:186-91. doi: 10.1097/bor.0000000000000028.
4. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med. 1987;82:421-6. doi: 10.1016/0002-9343(87)90441-4.
5. Dalbeth N, House ME, Aati O, Tan P, Franklin C, Horne A, et al. Urate crystal deposition in asymptomatic hyperuricaemia and symptomatic gout: a dual energy CT study. Ann Rheum Dis. 2015;74:908-11. doi: 10.1136/annrheumdis-2014-206397.
6. Howard RG, Pillinger MH, Gyftopoulos S, Thiele RG, Swearingen CJ, Samuels J. Reproducibility of musculoskeletal ultrasound for determining monosodium urate deposition: concordance between readers. Arthritis Care Res (Hoboken). 2011;63:1456-62. doi: 10.1002/acr.20527.
7. Pineda C, Amezcua-Guerra LM, Solano C, Rodriguez-Henriquez P, Hernandez-Diaz C, Vargas A, et al. Joint and tendon subclinical involvement suggestive of gouty arthritis in asymptomatic hyperuricemia: an ultrasound controlled study. Arthritis Res Ther. 2011;13:R4. doi: 10.1186/ar3223.
8. De Miguel E, Puig JG, Castillo C, Peiteado D, Torres RJ, Martin-Mola E. Diagnosis of gout in patients with asymptomatic hyperuricaemia: a pilot ultrasound study. Ann Rheum Dis. 2012;71:157-8. doi: 10.1136/ard.2011.154997.
9. Dalbeth N, Aati O, Kalluru R, Gamble GD, Horne A, Doyle AJ, et al. Relationship between structural joint damage and urate deposition in gout: a plain radiography and dual-energy CT study. Ann Rheum Dis. 2014. doi: 10.1136/annrheumdis-2013-204273.
10. Naredo E, Uson J, Jiménez-Palop M, Martínez A, Vicente E, Brito E, et al. Ultrasound-detected musculoskeletal urate crystal deposition: which joints and what findings should be assessed for diagnosing gout? Ann Rheum Dis. 2014;73:1522-8. doi: 10.1136/annrheumdis-2013-203487.
11. Mandel NS, Mandel GS. Monosodium urate monohydrate, the gout culprit. J Am Chem Soc. 1976;98:2319-23. doi: 10.1021/ja00424a054.
12. Perrin CM, Dobish MA, Van Keuren E, Swift JA. Monosodium urate monohydrate crystallization. CrystEngComm. 2011;13:1111-7. doi: 10.1039/C0CE00737D.
13. Mersmann A. Physical and chemical properties of crystalline systems. In: Mersmann A, editor. Crystallization technology handbook. 2nd ed. New York: Marcel Dekker, Inc.; 2001. p. 1-44.
14. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339. doi: 10.1136/bmj.b2535
15. Silberberg MS. Solubility and molecular structure. Principles of general chemistry. 3rd ed. New York: McGraw-Hill Education; 2012.
16. Allen DJ, Milosovich G, Mattocks AM. Inhibition of monosodium urate needle crystal growth. Arthritis Rheum. 1965;8:1123-33. doi: 10.1002/art.1780080611.
17. Allen DJ, Milosovich G, Mattocks AM. Crystal growth of sodium acid urate. J Pharm Sci. 1965;54:383-6. doi: 10.1002/jps.2600540308.
18. Wilcox WR, Khalaf A, Weinberger A, Kippen I, Klinenberg JR. Solubility of uric acid and monosodium urate. Med Biol Eng. 1972;10:522-31. doi: 10.1007/BF02474201.
19. Loeb JN. The influence of temperature on the solubility of monosodium urate. Arthritis Rheum. 1972;15:189-92. doi: 10.1002/art.1780150209.
20. Kippen I, Klinenberg JR, Weinberger A, Wilcox WR. Factors affecting urate solubility in vitro. Ann Rheum Dis. 1974;33:313-7. doi: 10.1136/ard.33.4.313.
21. Calvert PD, Fiddis RW, Vlachos N. Crystal growth of monosodium urate monohydrate. Colloids Surf. 1985;14:97-107. doi: 10.1016/0166-6622(85)80044-5.
22. Khalaf AA, Wilcox WR. Solubility and nucleation of monosodium urate in relation to gouty arthritis. J Cryst Growth. 1973;20:227-32. doi: 10.1016/0022-0248(73)90009-2.
23. Lam Erwin C-Y, Nancollas GH. The crystallization and dissolution of sodium urate. J Cryst Growth. 1981;53:215-23. doi: 10.1016/0022-0248(81)90068-3.
24. Seegmiller JE. The acute attack of gouty arthritis. Arthritis Rheum. 1965;8:714-25. doi: 10.1002/art.1780080431.
25. McNabb RA, McNabb FMA. Physiological chemistry of uric acid: solubility, colloid and ion-binding properties. Comp Biochem Physiol. 1980;67:27-34. doi: 10.1016/0300-9629(80)90405-3.
26. Füredi-Milhofer H, Babić-Ivaniɥić V, Milat O, Brown WE, Gregory TM. Precipitation of sodium acid urate from electrolyte solutions. J Cryst Growth. 1987;83:572-80. doi: 10.1016/0022-0248(87)90252-1.
27. Wilcox WR, Khalaf AA. Nucleation of monosodium urate crystals. Ann Rheum Dis. 1975;34:332-9. doi: 10.1136/ard.34.4.332.
28. Katz WA, Schubert M. The interaction of monosodium urate with connective tissue components. J Clin Invest. 1970;49:1783-9. doi: 10.1172/JCI106396.
29. Perricone E, Brandt KD. Enhancement of urate solubility by connective tissue. I. Effect of proteoglycan aggregates and buffer cation. Arthritis Rheum. 1978;21:453-60. doi: 10.1002/art.1780210409.
30. Laurent TC. Solubility of sodium urate in the presence of chondroitin-4-sulphate. Nature. 1964;202:1334. doi: 10.1038/2021334a0.
31. Burt HM, Dutt YC. Growth of monosodium urate monohydrate crystals: effect of cartilage and synovial fluid components on in vitro growth rates. Ann Rheum Dis. 1986;45:858-64. doi: 10.1136/ard.45.10.858.
32. Dorner RW, Weiss TD, Baldassare AR, Moore TL, Zuckner J. Plasma and synovial fluid as solvents for monosodium urate. Ann Rheum Dis. 1981;40:70-4. doi: 10.1136/ard.40.1.70.
33. Mullin JW. Nucleation of monosodium urate crystals. Crystallization. 4th ed. Oxford: Butterworth Heinemann; 2001.
34. Martillo MA, Nazzal L, Crittenden DB. The crystallization of monosodium urate. Curr Rheumatol Rep. 2014;16:400. doi: 10.1007/s11926-013-0400-9.
35. Oliviero F, Scanu A, Punzi L. Metabolism of crystals within the joint. Reumatismo. 2011;63:221-9. doi: 10.4081/reumatismo.2011.221.
36. H-k T, Wilcox WR, Cooper SM. Crystallization of monosodium urate and calcium urate at 37°C. J Colloid Interface Sci. 1980;77:195-201.
37. Tak HK, Cooper SM, Wilcox WR. Studies on the nucleation of monsodium urate at 37°C. Arthritis Rheum. 1980;23:574-80. doi: 10.1002/art.1780230509.
38. McGill NW, Dieppe PA. The role of serum and synovial fluid components in the promotion of urate crystal formation. J Rheumatol. 1991;18:1042-5.
39. McGill NW, Dieppe PA. The effect of biological crystals and human serum on the rate of formation of crystals of monosodium urate monohydrate in vitro. Br J Rheumatol. 1991;30:107-11. doi: 10.1093/rheumatology/30.2.107.
40. McGill NW, Dieppe PA. Evidence for a promoter of urate crystal formation in gouty synovial fluid. Ann Rheum Dis. 1991;50:558-61. doi: 10.1136/ard.50.8.558.
41. Perl-Treves D, Addadi L. A structural approach to pathological crystallizations. Gout: the possible role of albumin in sodium urate crystallization. Proc R Soc Lond B Biol Sci. 1988;235:145-59. doi: 10.1007/s11926-013-0400-9.
42. Kaneko K, Maru M. Determination of urate crystal formation using flow cytometry and microarea X-ray diffractometry. Anal Biochem. 2000;281:9-14. doi: 10.1006/abio.2000.4543.
43. Roddy E, Zhang W, Doherty M. Are joints affected by gout also affected by osteoarthritis? Ann Rheum Dis. 2007;66:1374-7. doi: 10.1136/ard.2006.063768.
44. Grassi W, Meenagh G, Pascual E, Filippucci E. "Crystal clear"-sonographic assessment of gout and calcium pyrophosphate deposition disease. Semin Arthritis Rheum. 2006;36:197-202. doi: 10.1016/j.semarthrit.2006.08.001.
45. Kanevets U, Sharma K, Dresser K, Shi Y. A role of IgM antibodies in monosodium urate crystal formation and associated adjuvanticity. J Immunol. 2009;182:1912-8. doi: 10.4049/jimmunol.0803777.
46. Kam M, Perl-Treves D, Caspi D, Addadi L. Antibodies against crystals. FASEB J. 1992;6:2608-13.
47. Kam M, Perl-Treves D, Sfez R, Addadi L. Specificity in the recognition of crystals by antibodies. J Mol Recognit. 1994;7:257-64. doi: 10.1002/jmr.300070404.
48. Burt HM, Dutt YC. Crystallization of monosodium urate monohydrate. J Cryst Growth. 1989;94:15-22. doi: 10.1016/0022-0248(89)90597-6.
49. Tak HK, Wilcox WR, Cooper SM. The effect of lead upon urate nucleation. Arthritis Rheum. 1981;24:1291-5. doi: 10.1002/art.1780241009.
50. Sattar S, Carroll MJ, Sargeant AA, Swift JA. Structure of a lead urate complex and its effect on the nucleation of monosodium urate monohydrate. CrystEngComm. 2008;10:155-7. doi: 10.1039/B715586G.
51. Fiddis RW, Vlachos N, Calvert PD. Studies of urate crystallisation in relation to gout. Ann Rheum Dis. 1983;42:12-5. doi: 10.1136/ard.42.Suppl-1.12.
52. McGill NW, Hayes A, Dieppe PA. Morphological evidence for biological control of urate crystal formation in vivo and in vitro. Scand J Rheumatol. 1992;21:215-9. doi: 10.3109/03009749209099227.
53. Pascual E, Martinez A, Ordonez S. Gout: the mechanism of urate crystal nucleation and growth. A hypothesis based in facts. Joint Bone Spine. 2013;80:1-4. doi: 10.1016/j.jbspin.2012.08.012.
54. Hayes A, Turner IG, Powell KA, Dieppe PA. Crystal aggregates in articular cartilage as observed in the SEM. J Mater Sci Mater Med. 1992;3:75-8. doi: 10.1007/BF00702948.
55. Konttinen YT, Mandelin J, Li TF, Salo J, Lassus J, Liljeström M, et al. Acidic cysteine endoproteinase cathepsin K in the degeneration of the superficial articular hyaline cartilage in osteoarthritis. Arthritis Rheum. 2002;46:953-60. doi: 10.1002/art.10185.
56. Lang A, Hörler D, Baici A. The relative importance of cysteine peptidases in osteoarthritis. J Rheumatol. 2000;27:1970-9.
57. Morko JP, Söderström M, Säämänen AK, Salminen HJ, Vuorio EI. Up regulation of cathepsin K expression in articular chondrocytes in a transgenic mouse model for osteoarthritis. Ann Rheum Dis. 2004;63:649-55. doi: 10.1136/ard.2002.004671.